NEW YORK (GenomeWeb News) - Transgenomic said yesterday that it has struck agreements with two undisclosed pharmaceutical companies to provide genetic mutation discovery services for two Phase II clinical trials.

The company said the deals will be worth a total of $500,000 in the first half of 2008, but it did not disclose the names of the companies involved or provide further financial details.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.